ASCO– tag –
-
FDA Approves Orca-T, First Regulatory T-Cell Therapy to Improve Chronic GVHD-Free Survival in Blood Cancer Patients Undergoing Allogeneic HSCT
American Society of Clinical Oncology (ASCO) Post USA Overview The US FDA has approved Orca-T (Tregzi, Orca Bio), the first regulatory T-cell (Treg)-based immunotherapy to improve chronic graft-versus-host disease (GVHD)-free survival in... -
ASCO 2026 Highlights CAR-T Cell Therapy Evolution in Multiple Myeloma: Focus on Rapid Manufacturing, Dual-Targeting, and Lentiviral Approaches
YouTube (OncUpdates) USA Overview A YouTube video featuring Dr. Hamza Hashmi discussed the latest advancements in CAR-T therapy for multiple myeloma at ASCO 2026. CAR-T therapy has evolved from a last-resort treatment to a viable option ... -
ASCO 2026 Emphasizes ‘Less Is More’: In Vivo CAR-T and Minimally Invasive, Highly Efficient Cancer Therapies Take Center Stage
Everest Clinical Research USA Overview ASCO 2026 highlighted 'Less Is More' as a guiding principle for future cancer care, with significant attention on evolving CAR-T cell therapies, particularly in vivo CAR-T approaches that engineer i... -
Allogeneic BCMA CAR T Therapy CB-011 Achieves Deep Responses and Confirms Immune Cloaking in Multiple Myeloma Phase 1 Trial
The ASCO Post USA Overview CB-011, the first allogeneic anti-BCMA CAR T-cell therapy incorporating immune cloaking technology, achieved a high overall response rate (ORR) in its Phase 1 CaMMouflage trial for relapsed/refractory heavily p... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ... -
Fate Therapeutics’ iPSC-Derived CAR T Therapy FT836 Shows Tumor Reduction and Favorable Safety Profile in KRASwt Colorectal Cancer Phase 1 Data at ASCO
GlobeNewswire (Fate Therapeutics Press Release) USA Overview Fate Therapeutics presented preliminary Phase 1 clinical data for its iPSC-derived, off-the-shelf CAR T-cell therapy, FT836, at the 2026 American Society of Clinical Oncology (... -
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da... -
Genprex’s Reqorsa® Gene Therapy Extends Progression-Free Survival in NSCLC Patients with High Trop-2/Low PTEN Biomarkers, ASCO 2026 Data Shows
Genprex, Inc. USA Overview Genprex, Inc. presented positive clinical data on predictive biomarkers for its Reqorsa® gene therapy in non-small cell lung cancer (NSCLC) patients at the 2026 ASCO Annual Meeting. The data indicates that pati...
12